glp 1 agonist eli lilly Medscape | Orforglipron, Lilly's investigational oral glucagon-like peptide receptor (GLP-1 RA), achieved positive phase 3 results for We're taking a closer look
Description
AMPLITUDE-O compared efpeglenatide to placebo in 4076 adults with T2DM and previous CV events or CV risk factors only [8]
Plainsboro, NJ: Novo Nordisk, Inc.;2019
Help managing GLP-1 associated side effects Speak to a health care provider about managing drug side effects and to rule out any other possible causes
doi: 10.1056/NEJMoa2505669
Very few people pay full list price, but it represents the ceiling that uninsured or uncovered patients face without intervention
About the author Maia Anderson Maia Anderson is a senior reporter at Healthcare Brew, where she focuses on pharma developments like GLP-1s and psychedelic medicine, pharmacies, and women's health.
